

Table No.	Table Captions	Page No.
1.1	Structure and mechanism of action of Anticonvulsant drugs	8
5.1	Chemical Structures and Physicochemical Properties of Compounds (3S1a-3S1i & 4S1a-4S1i)	57
5.2	Effect of the test compounds ( <b>Series 1</b> ) on s.c.PTZ induced seizures	66
5.3	Effect of the test compounds ( <b>Series 1</b> ) on pilocarpine-induced seizures	67
5.4	Effect of the test compounds ( <b>Series 1</b> ) on DMCM induced seizures	68
5.5	Effect of the test compounds ( <b>Series 1</b> ) on rota-rod performance test in mice	69
5.6	Percentage cell viability of the test compounds ( <b>Series 1</b> ) at different concentrations in neuroblastoma cell line (SH-SY5Y).	70
5.7	Effect of the test compound ( <b>4S1i</b> ) on haematological parameters of mice in 28 days repeated dose toxicity studies	72
5.8	Effect of the test compound ( <b>4S1i</b> ) on biochemical parameters of mice in 28 days repeated dose toxicity studies	72
5.9	PAMPA- BBB permeability ( $P_e$ ) value for commercial drugs, Tiagabine (Standard), selected leads of <b>Series 1</b>	74
5.10	Details of protein-ligand interactions of tiagabine, <b>4S1a</b> , <b>4S1b</b> , and <b>4S1i</b>	78
5.11	<i>In silico</i> drug likeliness properties of active compounds of <b>Series 1</b>	85
5.12	Chemical structures and physicochemical properties of compounds <b>5S2a-5S2y</b>	87
5.13	Permeability analysis using PAMPA-BBB assay ( <b>Series 2</b> )	101
5.14	Effect of the test compounds ( <b>Series 2</b> ) on s.c.PTZ induced seizures	103
5.15	Effect of the test compounds ( <b>Series 2</b> ) on DMCM induced seizures	104
5.16	Effect of the test compounds ( <b>Series 2</b> ) on rota-rod performance test in mice	104
5.17	Cell Viability of the test ( <b>Series 2</b> ) compounds at different concentrations in neuroblastoma cell line (SH-SY5Y).	105
5.18	Effect of test compound ( <b>5S2w</b> ) on hematological parameters of mice in 28 days repeated dose toxicity studies	106
5.19	Effect of test compound ( <b>5S2w</b> ) on biochemical parameters of mice in 28 days repeated dose toxicity studies	106
5.20	Details of protein-ligand interactions of tiagabine, <b>5S2d</b> , <b>5S2w</b> , and <b>5S2y</b>	111
5.21	<i>In silico</i> drug like properties of the active compounds of <b>Series 2</b>	115